AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$MD

Linynsky Laura A sold (to issuer) $161K of MD

Linynsky Laura A sold (to issuer) 6,000 shares of Pediatrix Medical Group, Inc. (MD) at $26.82 ($0.16M total) on 2026-09-10.

Original reporting
SEC EDGAR · Linynsky Laura A
Published Sep 14, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MD
Neutral
medium confidence
Mentioned
$MD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDNeutralLow
01

Why it matters

The director's sale is modest and does not suggest a material shift in confidence.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 3/10Timing: filed today

Background

Form 4 filings disclose insider transactions; traders monitor for signals.

Company-level read

Ticker impact

$MDNeutralMedium confidence
Context

Director Laura Linynsky sold 6,000 shares for $160,920 on Sep 10, 2026.

Expected impact

minimal downward pressure, likely negligible

Evidence & confidence

Sale size is small relative to float and recent price; no 10b5-1 plan.

Market effects

Sector

No broader sector impact; insider activity is company‑specific.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; watch for further disposals.

Key entities

  • company
    Pediatrix Medical Group, Inc.

    Healthcare services provider listed on NYSE under MD.

  • person
    Laura A. Linynsky

    Director of Pediatrix Medical Group.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MD insider trading history →

Related articles

AUG 11
$MDMedAI 8/10

Pediatrix Medical Group (MD) Q2 2026 Earnings Call Transcript

Pediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.

fool.com6 min
AUG 4
$MDMed

Pediatrix Medical Group Reports Second Quarter Results

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 4, 2026 - Pediatrix Medical G

SEC EDGAR 8-K6 min
JUL 15
$MDMed

Pediatrix Medical Group Provides Second Quarter Update

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1 FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Provides Second Quarter Update FORT LAUDERDALE, Fl

SEC EDGAR 8-K3 min
MAY 27
$MDHighAI 9/10

Does Pediatrix Medical Group (MD) Stock Look Better After Q1 Report?

Pediatrix Medical Group (NYSE:MD) reported Q1 2026 results on May 5. Revenue rose to $476.2 million from $458.4 million a year earlier, beating the $465.7 million analyst estimate, according to the company. Adjusted EBITDA increased to $58.2 million from $49.2 million. Adjusted EPS was $0.44 vs. $0.33 a year ago, above the $0.38 estimate. The company expects full-year 2026 adjusted EBITDA of $280–$300 million.

finance.yahoo.com5 min